Mfine Singapore (Wind-Down)
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
MFine was a Bengaluru-based digital health platform founded in December 2017 by former Myntra executives Ashutosh Lawania and Prasad Kompalli (later joined by Ajit Narayanan and Arjun Choudhary). Its AI-assisted platform offered on-demand doctor consultations across specialties, diagnostics, e-pharmacy and inpatient procedures, partnering with hospitals, clinics, diagnostics and radiology providers across 400+ Indian cities and 700+ diagnostic centres, processing about 300,000 transactions a month. Backed by Beenext, Stellaris Venture Partners, SBI Group, Prime Venture Partners and Heritas Capital, it raised close to $97 million and was last valued around $450 million after a $48 million Series C in September 2021. Its Singapore holding entity was wound down in 2023.
02 / Mfine Singapore (Wind-Down) FAILURE REASONS
Failure reasons
MFine collapsed under unsustainable unit economics exposed by the 2022 funding winter. It spent Rs 258 crore to earn just Rs 50 crore of revenue in FY22 - a burn ratio no amount of scale could fix, worsening from Rs 112 crore of spend for Rs 5 crore of revenue in FY20. When the funding environment froze, MFine was unable to pay salaries for the coming months: in May 2022 it laid off 500-600 employees, up to 75% of its workforce, dissolving most of its sales and marketing teams, after a planned follow-on financing fell through. Two months later it merged its diagnostics arm with LifeCell International to form 'LifeWell', which raised $80 million from OrbiMed - a rescue that preserved the business but ended MFine as a standalone company. The Singapore holding entity was subsequently wound down.
03 / EVENT HISTORY
Events in the structured record
- Founded
Former Myntra executives Ashutosh Lawania and Prasad Kompalli founded MFine in Bengaluru as an AI-assisted digital health platform.
- Series C
MFine raised $48 million in a Beenext-led Series C in September 2021, taking total funding to about $97 million at a valuation near $450 million.
- Collapse and merger
Out of funds, MFine laid off up to 75% of its workforce in May 2022; in July 2022 it merged with LifeCell International's diagnostics arm to form LifeWell, which raised $80 million from OrbiMed.
- Singapore wind-down
Per the company record, the Singapore holding entity was wound down in 2023; this date could not be independently verified.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Laid off about 75% of staff in May 2022 as the funding environment deteriorated.
- 02
Merged into LifeWell in July 2022 in an $80 million deal backed by OrbiMed.
- 03
The Singapore operation was wound down in 2023.